Table 4.
Secondary Outcome Results by Outcome Measure Category and Study
| Author and Year | Outcome Measure | Preintervention | Postintervention | %Change | P Value |
|---|---|---|---|---|---|
| CAUTI | |||||
| Epstein, 2016 [34] | CAUTI rate | NR | NR (decreased) | NR | .04 |
| Lynch, 2020 [36]a | CAUTI rate | 1.82/1000 catheter days | 1.64/1000 catheter days | −9.9 | NR |
| Munigala, 2019 [31] | CAUTI rate | 0.3/1000 PD | 0.3/1000 PD | 0 | .87 |
| Watson, 2020 [33] | CAUTI rate | 11.5/10 000 catheter days | 9.3/10 000 catheter days | −19.1 | .23 |
| Antimicrobial Use | |||||
| Demonchy, 2014 [27] | Guideline-concordant antimicrobial prescription rate | 31.7% | 47.6% | +50.2 (+15.9 absolute) | NR |
| Eudaley, 2019 [28] | Fluoroquinolone use | 42% | 15% | −64.3 (−27 absolute) | <.001 |
| Lee, 2021 [35] | Antimicrobial prescription per normal urinalysis rate | 48.7% | 43.4% | −10.8 (−5.3 absolute) | <.001 |
| Lynch, 2020 [36]a | Antimicrobial prescription per normal urinalysis rate | 35.9% | 31.0% | −13.6 (−4.9 absolute) | NR |
| Ourani, 2021 [32] | Antimicrobial prescription per normal urine culture rate | 45.1% | 9.0% | −80.0 (−36.1 absolute) | <.001 |
| Sarg, 2016 [38] | Antimicrobial DOT | 449/1000 PD | 425/1000 PD | −5.3 | NR |
| Watson, 2020 [33] | Antimicrobial DOT | 102.5/1000 PD | 86.9/1000 PD | −15.2 | <.01 |
Abbreviations: CAUTI, catheter-associated urinary tract infection; DOT, days of therapy; ED, emergency department; NR, not reported; PD, patient days.
a
Acute care results only.